SG11201405103SA - Compositions and methods for the treatment of hemoglobinopathies - Google Patents

Compositions and methods for the treatment of hemoglobinopathies

Info

Publication number
SG11201405103SA
SG11201405103SA SG11201405103SA SG11201405103SA SG11201405103SA SG 11201405103S A SG11201405103S A SG 11201405103SA SG 11201405103S A SG11201405103S A SG 11201405103SA SG 11201405103S A SG11201405103S A SG 11201405103SA SG 11201405103S A SG11201405103S A SG 11201405103SA
Authority
SG
Singapore
Prior art keywords
hemoglobinopathies
compositions
treatment
methods
Prior art date
Application number
SG11201405103SA
Inventor
Michael A Bender
Mark T Groudine
Barry L Stoddard
Ryo Takeuchi
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of SG11201405103SA publication Critical patent/SG11201405103SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201405103SA 2012-02-24 2013-02-22 Compositions and methods for the treatment of hemoglobinopathies SG11201405103SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603231P 2012-02-24 2012-02-24
PCT/US2013/027459 WO2013126794A1 (en) 2012-02-24 2013-02-22 Compositions and methods for the treatment of hemoglobinopathies

Publications (1)

Publication Number Publication Date
SG11201405103SA true SG11201405103SA (en) 2014-09-26

Family

ID=49006265

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201606959PA SG10201606959PA (en) 2012-02-24 2013-02-22 Compositions and methods for the treatment of hemoglobinopathies
SG11201405103SA SG11201405103SA (en) 2012-02-24 2013-02-22 Compositions and methods for the treatment of hemoglobinopathies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201606959PA SG10201606959PA (en) 2012-02-24 2013-02-22 Compositions and methods for the treatment of hemoglobinopathies

Country Status (18)

Country Link
US (2) US20150166969A1 (en)
EP (2) EP2836226B1 (en)
JP (2) JP6170080B2 (en)
KR (2) KR20180009383A (en)
CN (1) CN104284669A (en)
AU (2) AU2013222170B2 (en)
BR (1) BR112014020625A2 (en)
CA (1) CA2865129A1 (en)
DK (1) DK2836226T3 (en)
ES (1) ES2641840T3 (en)
HK (1) HK1249861A1 (en)
IL (2) IL234225B (en)
IN (1) IN2014DN07853A (en)
NZ (1) NZ630900A (en)
RU (2) RU2650811C2 (en)
SG (2) SG10201606959PA (en)
WO (1) WO2013126794A1 (en)
ZA (1) ZA201406187B (en)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
CA2865129A1 (en) 2012-02-24 2013-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
PE20190843A1 (en) 2012-05-25 2019-06-17 Emmanuelle Charpentier RNA ADDRESSING TO GENERIC DNA
RS60838B1 (en) * 2012-08-29 2020-10-30 Sangamo Therapeutics Inc Methods and compositions for treatment of a genetic condition
DK2925864T3 (en) 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
ES2883590T3 (en) 2012-12-12 2021-12-09 Broad Inst Inc Supply, modification and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014099750A2 (en) 2012-12-17 2014-06-26 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3578666A1 (en) 2013-03-12 2019-12-11 President and Fellows of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
CA2905432C (en) 2013-03-14 2021-09-14 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
EP3741868B1 (en) 2013-03-15 2024-05-22 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN115261411A (en) 2013-04-04 2022-11-01 哈佛学院校长同事会 Therapeutic uses of genome editing with CRISPR/Cas systems
CN116083487A (en) 2013-05-15 2023-05-09 桑格摩生物治疗股份有限公司 Methods and compositions for treating genetic conditions
WO2014197568A2 (en) 2013-06-04 2014-12-11 President And Fellows Of Harvard College Rna-guideded transcriptional regulation
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
DK3011031T3 (en) 2013-06-17 2020-12-21 Broad Inst Inc PERFORMANCE AND APPLICATION OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGET DIRECTION AND THERAPY
ES2767318T3 (en) 2013-06-17 2020-06-17 Broad Inst Inc Supply, modification and optimization of systems, methods and compositions to generate models and act on postmitotic cell diseases and disorders
CN105793425B (en) 2013-06-17 2021-10-26 布罗德研究所有限公司 Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
EP3019595A4 (en) * 2013-07-09 2016-11-30 Therapeutic uses of genome editing with crispr/cas systems
CA2917639C (en) 2013-07-10 2024-01-02 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CN106459995B (en) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 CRISPR-associated methods and compositions using dominant grnas
SI3068881T1 (en) * 2013-11-13 2019-05-31 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
EP3760719A1 (en) * 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
KR20160089527A (en) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
JP2017501149A (en) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using particle delivery components
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US9963689B2 (en) 2013-12-31 2018-05-08 The Regents Of The University Of California Cas9 crystals and methods of use thereof
SG10201805815YA (en) * 2014-01-08 2018-08-30 Harvard College Rna-guided gene drives
WO2015122967A1 (en) 2014-02-13 2015-08-20 Clontech Laboratories, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US9938521B2 (en) 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
US20170173083A1 (en) * 2014-03-26 2017-06-22 The Brigham And Women's Hospital, Inc. Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
WO2015148860A1 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta-thalassemia
WO2015148863A2 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3134130B1 (en) 2014-04-25 2019-06-12 Children's Medical Center Corporation Compositions and methods to treating hemoglobinopathies
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016025759A1 (en) * 2014-08-14 2016-02-18 Shen Yuelei Dna knock-in system
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
LT3194570T (en) * 2014-09-16 2021-09-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
CN107205353B (en) 2014-09-26 2021-03-19 谱赛科美国股份有限公司 Single Nucleotide Polymorphism (SNP) markers for stevia
KR20240013283A (en) 2014-12-03 2024-01-30 애질런트 테크놀로지스, 인크. Guide rna with chemical modifications
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
EP3702456A1 (en) 2014-12-24 2020-09-02 The Broad Institute, Inc. Crispr having or associated with destabilization domains
US20180002379A1 (en) * 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2016135559A2 (en) * 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
EP3262172A2 (en) * 2015-02-23 2018-01-03 Crispr Therapeutics AG Materials and methods for treatment of hemoglobinopathies
ES2884838T3 (en) 2015-04-06 2021-12-13 Univ Leland Stanford Junior Chemically modified guide RNA for CRISPR / CAS-mediated gene regulation
US10155938B2 (en) * 2015-04-14 2018-12-18 City Of Hope Coexpression of CAS9 and TREX2 for targeted mutagenesis
CN104805118A (en) * 2015-04-22 2015-07-29 扬州大学 Method for targeted knockout of specific gene of Suqin yellow chicken embryonic stem cell
WO2016178207A1 (en) * 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
EP3294873B1 (en) * 2015-05-08 2020-08-19 The Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
JP7030522B2 (en) * 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド Optimized CRISPR / CAS9 system and method for gene editing in stem cells
CN108026526B (en) 2015-06-09 2023-05-12 爱迪塔斯医药公司 CRISPR/CAS related methods and compositions for improving transplantation
CA2989831A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for genomic editing
CA2989858A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2996888A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Engineered crispr-cas9 nucleases
US9897378B2 (en) 2015-10-08 2018-02-20 Nyc Designed Inspirations Llc Cosmetic makeup sponge/blender container
EP4269577A3 (en) 2015-10-23 2024-01-17 President and Fellows of Harvard College Nucleobase editors and uses thereof
DK3368052T3 (en) * 2015-10-27 2022-03-14 Childrens Hospital Med Ct USE OF MAPK INHIBITORS TO REDUCE THE LOSS OF HEMATOPOETIC STEM CELLS DURING EX VIVO CULTIVATION AND GENE MANIPULATION
MX2018005611A (en) 2015-11-03 2018-11-09 Harvard College Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix.
ES2942309T3 (en) * 2015-11-04 2023-05-31 Vertex Pharma Materials and methods for the treatment of hemoglobinopathies
CA3003150A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
EP3371301A4 (en) 2015-11-04 2019-06-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN108779462A (en) * 2015-12-28 2018-11-09 诺华股份有限公司 Composition for treating hemoglobinopathy and method
AR107469A1 (en) 2016-01-27 2018-05-02 Oncorus Inc ONCOLITIC VIRAL VECTORS AND THEIR USES
US11530253B2 (en) 2016-02-25 2022-12-20 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
KR20230070331A (en) * 2016-03-14 2023-05-22 에디타스 메디신, 인코포레이티드 Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
LT3445388T (en) * 2016-04-18 2024-06-10 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
JP7259182B2 (en) 2016-04-25 2023-04-18 プレジデント アンド フェローズ オブ ハーバード カレッジ Hybridization chain reaction method for in situ molecular detection
WO2017191503A1 (en) * 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN109689865A (en) * 2016-07-25 2019-04-26 蓝鸟生物公司 BCL11A homing endonuclease variants, composition and application method
IL264565B1 (en) 2016-08-03 2024-03-01 Harvard College Adenosine nucleobase editors and uses thereof
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
CN106244555A (en) * 2016-08-23 2016-12-21 广州医科大学附属第三医院 A kind of method of efficiency improving gene targeting and the base in-situ remediation method in beta globin gene site
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
DK3510157T3 (en) 2016-09-08 2023-07-24 2Seventy Bio Inc PD-1 HOMING ENDONUCLASE VARIANTS, COMPOSITIONS AND METHODS OF USE
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
CA3050514A1 (en) 2017-01-27 2018-08-02 Children's Hospital Medical Center Methods of enhancing engraftment activity of hematopoietic stem cells
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
EP3601562A1 (en) 2017-03-23 2020-02-05 President and Fellows of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
BR112019021719A2 (en) 2017-04-21 2020-06-16 The General Hospital Corporation CPF1 VARIANT (CAS12A) WITH CHANGED PAM SPECIFICITY
EP3615664A4 (en) * 2017-04-24 2021-01-27 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Homology directed repair compositions for the treatment of hemoglobinopathies
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN111093714A (en) 2017-05-25 2020-05-01 通用医疗公司 Deamination using a split deaminase to restrict unwanted off-target base editors
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
WO2018220210A1 (en) * 2017-06-02 2018-12-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11779654B2 (en) 2017-10-04 2023-10-10 2Seventy Bio, Inc. PCSK9 endonuclease variants, compositions, and methods of use
KR20200086670A (en) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. Methods and compositions for attenuating antiviral delivery vector IgM responses
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US20210180091A1 (en) * 2017-10-26 2021-06-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
CN109722415B (en) * 2017-10-27 2021-01-26 博雅辑因（北京）生物科技有限公司 Hematopoietic stem cell culture composition, culture medium and hematopoietic stem cell culture method
KR20200106159A (en) * 2017-12-05 2020-09-11 버텍스 파마슈티칼스 인코포레이티드 CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
EP3749767A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2019150203A1 (en) 2018-02-05 2019-08-08 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US20200405642A1 (en) 2018-02-26 2020-12-31 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
US11981892B2 (en) 2018-04-16 2024-05-14 University Of Massachusetts Compositions and methods for improved gene editing
EP3784029A4 (en) * 2018-04-27 2022-04-20 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
US20200102563A1 (en) * 2018-10-02 2020-04-02 Exosome Therapeutics, Inc. Exosome loaded therapeutics for treating sickle cell disease
CA3122278A1 (en) * 2018-12-10 2020-06-18 Bluebird Bio, Inc. Homing endonuclease variants
US11384344B2 (en) 2018-12-17 2022-07-12 The Broad Institute, Inc. CRISPR-associated transposase systems and methods of use thereof
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
CA3236512A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020191246A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN110042124A (en) * 2019-04-25 2019-07-23 国家卫生健康委科学技术研究所 Genome base editor increases the kit of fetal hemoglobin level and application in human red blood cells
CN111939271A (en) * 2019-04-30 2020-11-17 博雅辑因（北京）生物科技有限公司 Method for predicting treatment effectiveness of hemoglobinopathy
KR20220002565A (en) * 2019-04-30 2022-01-06 에디진 인크. How to predict the effectiveness of treatment for dyshemoglobinosis
KR20220015425A (en) 2019-05-28 2022-02-08 셀렉타 바이오사이언시즈, 인크. Methods and compositions for attenuated antiviral transfer vector immune response
US20220380756A1 (en) * 2019-06-28 2022-12-01 Asc Therapeutics Inc. Methods and compositions for treating thalassemia or sickle cell disease
CA3153197A1 (en) 2019-10-03 2021-04-08 Ryan T. Gill Crispr systems with engineered dual guide nucleic acids
AU2020385006A1 (en) * 2019-11-15 2022-06-02 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
CN112979823B (en) * 2019-12-18 2022-04-08 华东师范大学 Product and fusion protein for treating and/or preventing beta-hemoglobinopathy
GB2614813A (en) 2020-05-08 2023-07-19 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP2023526007A (en) * 2020-05-13 2023-06-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル A base-editing approach for the treatment of β-hemoglobin disorders
CN116887853A (en) * 2020-12-21 2023-10-13 2赛文缇生物公司 Compositions and methods for site-directed mutagenesis
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
CN113481184A (en) * 2021-08-06 2021-10-08 北京大学 Fusion proteins and methods of use thereof
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN114457119B (en) * 2022-04-11 2022-08-12 中吉智药(南京)生物技术有限公司 Application of lentiviral vector in preparation of drug for treating beta-thalassemia
EP4273242A1 (en) * 2022-05-03 2023-11-08 ETH Zurich Crispr-based modification of human hbd gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
EP2522723B1 (en) 2003-01-28 2014-12-03 Cellectis Custom-made meganuclease and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
CN101679959A (en) 2007-02-19 2010-03-24 赛莱克蒂斯公司 LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof
WO2009013559A1 (en) * 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
ES2738980T3 (en) * 2008-09-15 2020-01-28 Childrens Medical Ct Corp Modulation of BCL11A for the treatment of hemoglobinopathies
WO2011156430A2 (en) * 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
EP4062927A1 (en) * 2011-02-28 2022-09-28 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
CA2865129A1 (en) 2012-02-24 2013-08-29 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
RS60838B1 (en) * 2012-08-29 2020-10-30 Sangamo Therapeutics Inc Methods and compositions for treatment of a genetic condition

Also Published As

Publication number Publication date
CN104284669A (en) 2015-01-14
NZ630900A (en) 2016-10-28
KR20140128453A (en) 2014-11-05
AU2017201235A1 (en) 2017-03-16
US20150166969A1 (en) 2015-06-18
SG10201606959PA (en) 2016-09-29
WO2013126794A1 (en) 2013-08-29
EP2836226A4 (en) 2016-04-13
RU2650811C2 (en) 2018-04-17
IL234225B (en) 2019-05-30
JP2015516146A (en) 2015-06-11
US10619140B2 (en) 2020-04-14
EP3272356A1 (en) 2018-01-24
AU2017201235C1 (en) 2018-11-01
IL266582A (en) 2019-07-31
KR101833589B1 (en) 2018-03-02
HK1249861A1 (en) 2018-11-16
JP6170080B2 (en) 2017-07-26
RU2014138491A (en) 2016-04-10
KR20180009383A (en) 2018-01-26
BR112014020625A2 (en) 2017-07-04
JP2017148056A (en) 2017-08-31
RU2018109507A (en) 2019-02-28
CA2865129A1 (en) 2013-08-29
EP2836226A1 (en) 2015-02-18
AU2013222170A1 (en) 2014-10-02
AU2013222170B2 (en) 2017-01-05
ES2641840T3 (en) 2017-11-14
EP2836226B1 (en) 2017-06-28
ZA201406187B (en) 2018-05-30
AU2017201235B2 (en) 2018-08-02
US20170298329A1 (en) 2017-10-19
DK2836226T3 (en) 2017-09-18
IN2014DN07853A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
IL266582A (en) Compositions and methods for the treatment of hemoglobinopathies
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
HK1204461A1 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
HK1209788A1 (en) Methods and compositions for the treatment of lysosomal storage diseases
EP2847152A4 (en) Compositions and methods for the treatment of metabolic syndrome
EP2736528A4 (en) Compositions and methods for the treatment of hiv
IL225239A0 (en) Compositions for the treatment of acne and related disorders
IL238177A0 (en) Methods and compositions for the treatment of cancer
EP2688594A4 (en) Methods and compositions for the treatment of cancer
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2884984A4 (en) Therapeutic compositions and methods
DK3292875T3 (en) Compositions and methods for treating diseases
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
HK1208598A1 (en) Methods and compositions for treating pain
ZA201408055B (en) Compositions and methods for the treatment of local pain
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2895186A4 (en) Therapeutic compositions and related methods
EP2800568A4 (en) Compositions, methods of use, and methods of treatment
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
ZA201408053B (en) Compositions and methods for the treatment of metabolic syndrome
EP2825184A4 (en) Compositions and methods for treatment of pain
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same